These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39431008)

  • 1. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.
    Liao Y; Zhao C; Pan Y; Guo Y; Liu L; Wu J; Zhang Y; Rao L; Li Q
    Theranostics; 2024; 14(16):6409-6425. PubMed ID: 39431008
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
    Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
    Small; 2024 Aug; 20(31):e2311702. PubMed ID: 38456371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
    Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
    Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Delivery Nanobooster to Enhance Immunogenic Cell Death for Cancer Chemoimmunotherapy.
    Yan C; Zhao Y; Liu X; Jiang Y; Li Q; Yang L; Li X; Luo K
    ACS Appl Mater Interfaces; 2024 Jul; 16(26):33169-33181. PubMed ID: 38915234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.
    Wei M; Wang X; Mo Y; Kong C; Zhang M; Qiu G; Tang Z; Chen J; Wu F
    Int J Nanomedicine; 2024; 19():7215-7236. PubMed ID: 39050875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
    Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
    Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
    Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
    Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
    J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy.
    Liu Y; Xu C; Zhang L; Xu G; Yang Z; Xiang L; Jiao K; Chen Z; Zhang X; Liu Y
    Sci Adv; 2024 Sep; 10(37):eadi7764. PubMed ID: 39259785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosynthetic MnSe nanobomb with low Mn content activates the cGAS-STING pathway and induces immunogenic cell death to enhance antitumour immunity.
    Gao W; Wang Y; Wang P; Kan W; Wang M; Li H; Wang X; Yuan P; Ma Y; Zhang J; Tian G; Zhang G
    Acta Biomater; 2024 Aug; 184():383-396. PubMed ID: 38936753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Jeon SH; You G; Park J; Chung Y; Park K; Kim H; Jeon J; Kim Y; Son WC; Jeong DS; Shin EC; Lee JY; Han DH; Jung J; Park SH
    Clin Cancer Res; 2024 Sep; 30(18):4155-4166. PubMed ID: 38743752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy.
    Gupta A; Niveria K; Chandpa HH; Singh M; Kumar V; Panda AK; Meena J
    Drug Deliv Transl Res; 2024 Oct; 14(10):2712-2726. PubMed ID: 38347431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
    Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
    ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.